By Jean-Louis Briau-Geneste - Founder & Editorial Director, PHARMAnetwork Ltd
The manufacturing of highly potent drugs is a very rigorous
procedure that faces significant challenges, including
high capital investments, extensive operational expertise, access to advanced infrastructure and technologies, and highly qualified personnel. As a result,
outsourcing has become a preferred economic
model in this area, offering inc reased flexibility, contained costs, and controlled drug
launches.
The report evaluates the current opportunities and future growth potential of
the HPAPI and cytotoxic drug manufacturing market over the coming years. In
the second part, the report presents the
landscape of CDMOs in Europe and the
USA specializing in the manufacture of
cytotoxic and highly potent drugs. The
third part analyzes the recent expansions
undertaken by several CDMOs, and in the
fourth, the CDMOs (Aenova, CordenPharma,
Fareva, PCI and Recipharm) present their
strategy, challenges and know-how in the manufacturing of cytotoxic and highly potent drugs
Read in the digital edition
- PHARMAnetwork magazine n° 59, page 26
